ONERA-HEALTH
Onera Health announced today the introduction of its first Onera Biomedical-Lab-on-Chip™. The biomedical sensor system-on-chip acquires and processes multiple biosignals and is designed for a broad range of wearable health applications and devices, offering many solutions and opportunities for innovation in the medical, wellness and fitness space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005188/en/
"We are thrilled to introduce Onera Biomedical-Lab-on-Chip™ in the lead-up to CES 2022 in Las Vegas this week. It's the perfect opportunity to showcase our chip to the wearables ecosystem! Our highly integrated and comprehensive biosignal sensor hub is a unique solution that promises to revolutionize this competitive field. It combines clinical-grade physiological measurements and analysis with ultra-low-power consumption, enabling the development of miniaturized and high-quality wearable devices. Launching this powerful chip as a stand-alone product within our portfolio, not just as part of our innovative Onera diagnostic and monitoring solutions, is yet another exciting step for our company", explains Ruben de Francisco, Founder and CEO of Onera.
The Dutch-American company leveraged from its deep tech roots and close partnership with imec, a world-leading research and innovation hub in nanoelectronics and digital technologies, with the development of the ultra-low-power biosignal chip.
“Seeing Onera bring this ground-breaking system-on-chip to the market is what imec’s unique experience in semiconductor devices for MedTech applications, and our imec ecosystem, is all about - enabling nano- and digital technology innovation that promises a significant impact on the quality of life”, added Rudi Cartuyvels, COO of imec.
Onera Biomedical-Lab-on-Chip™ is a multi-channel sensor readout system with integrated data processing, power management, and interfacing features. It offers a wide range of on-chip biomedical sensor readouts, including 10 readouts for ExG, covering EEG, ECG, EMG, and EOG, 2 bioimpedance readouts, and 2 readouts for photoplethysmography. The data can be processed by on-chip digital filters and accelerators, supported by a powerful ARM Cortex M4f. The chip features several standard wired interfaces such as UART, SPI, I2C, and I2S. The chip fully operates on a single power source which can be anything between 0.8V and 3.6V, since power management is also integrated on-chip. In addition, a large amount of SRAM and embedded FLASH is available, supporting the large number of data streams with accurate data-synchronization as an essential feature.
To support the development and transition to commercialization of Onera’s products, the company has ramped-up hiring recently, including adding to its strong leadership team.
From the 5th to the 8th of January 2022, Onera Health exhibits its Onera STS I Polysomnography Solution and its Onera Biomedical-Lab-on-Chip™ at CES 2022 in Las Vegas, booth 8570 in the LVCC - North Hall.
About Onera
Onera Health is a leader in transforming diagnostics and monitoring. Their breakthrough products and technologies are poised to help millions of people struggling with health ailments and chronic conditions in a variety of medical fields, including sleep, neuro, cardiac and respiratory care, ultimately improving the health and quality of life for patients around the world. The company’s innovative solutions provide comprehensive physiological and health-related data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. For more information, go to www.onerahealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.
Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development26.11.2025 11:15:00 CET | Press release
Modon joins a consortium of investors to elevate Wellington International equestrian showgrounds and develop an ultra-luxury destination integrating residential, hospitality and sports assets in Wellington, Palm Beach County, FloridaStrengthens Modon’s global presence and enables knowledge exchange across large-scale mixed-use, hospitality and lifestyle developments Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/ Aerial shot of Wellington International (Photo: AETOSWire) Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championshi
Epassi Announces Leadership Transition26.11.2025 11:00:00 CET | Press release
Nickyl Raithatha to join as Group CEOPekka Rantala to remain on Board as Non-Executive Chair Epassi Group, a European leader in digital employee benefits technology, today announced that Nickyl Raithatha will join as Chief Executive Officer. Nickyl will assume the role in 2026. Pekka Rantala, who has served as CEO since September 2019, will remain on the Board as Non-Executive Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126015983/en/ Pekka Rantala and Nickyl Raithatha Over the past six years, Epassi Group has evolved from a Nordic success story into one of Europe’s leading SaaS employee benefits and wellbeing platforms. The company has expanded both its geographic footprint as well as its product portfolio, driven by a powerful combination of strong organic growth and strategic acquisitions, with backing from TA Associates and Warburg Pincus. Today it has a presence in ten countries and a team of 1,000 people. W
Enerin raises €15 million Series A to industrialise modular high-temperature heat pumps for global industry26.11.2025 10:00:00 CET | Press release
Norway-based technology leader in industrial heat pumps, Enerin AS, has raised €15 million in an oversubscribed Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy. The investment marks Enerin’s transition from technology pioneer to serial production. Proceeds will expand commercial and manufacturing operations, and accelerate next-generation development. Johnson Controls’ participation provides strategic validation and global reach from one of the world’s leading providers of energy systems. Enerin, a technology leader in high-temperature heat pumps, has raised €15 million (NOK 180 million) in a Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy, with participation from PSV Hafnium and Momentum. “This investment marks our shift from pioneering to full industrialisation, bringing proven high-temperature technology from Norway to industries worldwide,” said Arne Høeg, Founder and CEO of Enerin. “Industrial companie
IQM to Invest Over €40 Million to Expand Finland Production Facility, Accelerate Innovation and Fuel Growth26.11.2025 09:49:00 CET | Press release
The new facility will produce advanced quantum chips for error corrected quantum computers, almost double the cleanroom space and system assembly line capacity to produce up to 30 quantum computers per year. The integrated quantum computer production line will be one of the world’s most advanced of its kind combining fabrication of quantum chips and system assembly. The expansion is expected to be completed by the first quarter of 2026. The expansion is part of IQM’s long-term commitment to scale its infrastructure and execute the ambitious technology roadmap aiming at 1M quantum computers by 2033. IQM Quantum Computers, a global leader in superconducting quantum computers, today announced over €40 million investment to expand its state-of-the-art production facility in Finland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126943986/en/ This strategic expansion will accelerate the development, fabrication and testing of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom